INSEMPRA
25.5.2023 08:01:30 CEST | Business Wire | Press release
Insempra, a biology-powered company enabling businesses to make superior products with nature, and Fibers365, a company offering chemical-free processed fibers and substrates from annual plants, today announce that they are working together to develop and scale sustainable second-generation (2G) feedstock for the commercial production of fermentation-based ingredients.
2G feedstocks, also known as lignocellulosic feedstocks, are a key area of research and development in biotechnology as the industry is facing a growing need in the application of these in fermentation processes. Fast moving consumer good companies, for example, are demanding sustainably procured raw materials. By utilizing agricultural residues, 2G feedstock has the potential to reduce greenhouse gas emissions by replacing fossil-based and de-forestation-based ingredients and consumer products. Insempra has built a broad toolbox to use feedstocks derived from agricultural wastes and also upcoming intermediates originating from carbon capture methods.
The Fibers365 patented, modular, farm level Steam Fiber Plants allow the competitive extraction of functional cellulosic fibers, lignin and sugars from multi feedstock non-wood biomass. The sugars, currently used for the generation of biogas, can be further valorized by producing high-value products via fermentation for various industrial applications.
“By working together with Insempra, we are combining our unique 2G feedstock derived from agricultural side streams with the highly advanced fermentation technology platform needed to scale and make this sustainable feedstock accessible to broader applications.” said Stefan Radlmayr, Founder and Managing Partner of Fibers365.
One of the primary challenges with 2G feedstocks is the intrinsic material stability of lignocellulosic materials. Unlike first-generation feedstocks (e.g., those derived from beets, corn, sugarcane), which contain easily accessible sugars, lignocellulosic biomass is composed of complex structures that require pre-treatment and enzymatic hydrolysis to release the sugars. Developing efficient and cost-effective pre-treatment methods and robust enzymatic cocktails for biomass deconstruction is a key challenge in the adoption of 2G feedstocks at scale.
Insempra has successfully tested Fibers365’s 2G feedstock derived from agricultural waste streams (e.g., wheat straw) with its proprietary fermentation technology platform. Insempra is using this technology for the development of speciality lipids for application in the beauty and personal care as well as nutraceuticals and food industries. In addition to speciality lipids, Insempra is also working on the production of protein fibers and high-value functional ingredients with 2G feedstocks from agricultural waste.
“Using second-generation feedstocks in our manufacturing processes has always been one of our priorities as a biology-powered business. We are tremendously excited about the potential this technology not only has for our businesses, but for the whole industry.” said Jens Klein, CEO & Founder of Insempra.
By working together, Insempra and Fibers365 tackle the challenge of scaling and aim to maximize the potential of 2G feedstocks to support their mission to manufacture at scale in collaboration with nature, thereby contributing to a more sustainable and circular future.
About Insempra
Insempra GmbH, Munich (Germany), is a biology-powered company enabling businesses to make superior products with nature. We combine bioscience and technology to grow matter for new and better products.
For too long, businesses have relied on chemical industrialization processes and petrochemicals, depleting our planet’s limited resources. That’s why we are committed to drive the regenerative revolution to manufacture at scale in collaboration with nature.
Led by a hand-picked team of biologists, technologists, and entrepreneurs with rebel hearts, Insempra is here to create a new school of thought and collective action. The time to restore the balance between people and the planet is now. We don't wait for change. We do what needs to be done to grow a better future.
Learn more about Insempra at insempra.bio
About Fibers365
Fibers365 GmbH, Lenningen (Germany), offers a unique, multi-feedstock biomass processing technology for annual plants to provide functional, competitive non wood biomass products such as virgin fibers for paper, packaging and textile applications as well as high value biopolymer and fertilizer side streams, produced with carbon neutral bioenergy. The products are extracted from agricultural residues such as straw by a chemical-free, regional, farm level steam explosion pulping technology, allowing easy separation of cellulosic fibers from sugars, lignin, organic acid and minerals. The use of annually regrown plants allows to compensate CO2 emissions from processing and product consumption almost instantly, by closing a yearly carbon loop.
Learn more about Fibers365 at fibers365.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005793/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
